Literature DB >> 22808303

Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.

Salih Taşkın1, Yeliz Gümüş, Saba Kiremitçi, Korhan Kahraman, Ayşe Sertçelik, Fırat Ortaç.   

Abstract

Diffuse peritoneal malignant mesothelioma is a rare, progressive, and ultimately fatal disease and it can present as primary peritoneal carcinoma or ovarian cancer. Differential diagnosis is important to establish appropriate management. In this article the clinical presentation, immunuhistochemical and histopathological features of 8 diffuse peritoneal malignant mesothelioma cases presented as peritoneal carcinoma or ovarian cancer are evaluated. According to findings of all reported cases, we concluded that clinical distinction of malignant mesothelioma from ovarian cancer or peritoneal adenocarcinoma is very difficult. Differential diagnosis is reliably achieved by immune profile of the tumors with a systematic approach of both positive and negative mesothelioma markers.

Entities:  

Keywords:  Peritoneal mesotheliomas; ovarian cancer; peritoneal adenocarcinoma

Mesh:

Substances:

Year:  2012        PMID: 22808303      PMCID: PMC3396062     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

1.  Primary malignant gonadal mesotheliomas and asbestos.

Authors:  R L Attanoos; A R Gibbs
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

Review 2.  Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.

Authors:  W G McCluggage; N Wilkinson
Journal:  Histopathology       Date:  2005-09       Impact factor: 5.087

3.  Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas.

Authors:  P B Clement; R H Young; R E Scully
Journal:  Am J Surg Pathol       Date:  1996-09       Impact factor: 6.394

4.  Mesothelial neoplasms presenting as, and mimicking, ovarian cancer.

Authors:  Haresh Mani; Maria J Merino
Journal:  Int J Gynecol Pathol       Date:  2010-11       Impact factor: 2.762

5.  Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.

Authors:  P Chu; E Wu; L M Weiss
Journal:  Mod Pathol       Date:  2000-09       Impact factor: 7.842

6.  Value of mesothelin immunostaining in the diagnosis of mesothelioma.

Authors:  Nelson G Ordóñez
Journal:  Mod Pathol       Date:  2003-03       Impact factor: 7.842

7.  Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.

Authors:  G H Eltabbakh; M S Piver; R E Hempling; F O Recio; M E Intengen
Journal:  J Surg Oncol       Date:  1999-01       Impact factor: 3.454

8.  Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.

Authors:  Albert Y Chu; Leslie A Litzky; Theresa L Pasha; Geza Acs; Paul J Zhang
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

9.  Papillary mesothelioma of ovary.

Authors:  B J Addis; H Fox
Journal:  Histopathology       Date:  1983-03       Impact factor: 5.087

10.  Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.

Authors:  J Goldblum; W R Hart
Journal:  Am J Surg Pathol       Date:  1995-10       Impact factor: 6.394

View more
  8 in total

Review 1.  Advances in malignant peritoneal mesothelioma.

Authors:  Shoubo Cao; Shi Jin; Jingyan Cao; Jing Shen; Jing Hu; Dehai Che; Bo Pan; Jiawen Zhang; Xiaoxi He; Dian Ding; Feifei Gu; Yan Yu
Journal:  Int J Colorectal Dis       Date:  2014-10-21       Impact factor: 2.571

2.  Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

Authors:  Nina R Shah; Isabelle Tancioni; Kristy K Ward; Christine Lawson; Xiao Lei Chen; Christine Jean; Florian J Sulzmaier; Sean Uryu; Nichol L G Miller; Denise C Connolly; David D Schlaepfer
Journal:  Gynecol Oncol       Date:  2014-04-27       Impact factor: 5.482

Review 3.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Authors:  Brooke T Mossman; Arti Shukla; Nicholas H Heintz; Claire F Verschraegen; Anish Thomas; Raffit Hassan
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307

4.  Primary Ovarian Mesothelioma: A Case Series with Electron Microscopy Examination and Review of the Literature.

Authors:  Luigi Vimercati; Domenica Cavone; Maria Celeste Delfino; Biagio Bruni; Luigi De Maria; Antonio Caputi; Stefania Sponselli; Roberta Rossi; Leonardo Resta; Francesco Fortarezza; Federica Pezzuto; Gabriella Serio
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

5.  A case of unsuspected peritoneal mesothelioma occurring with colonic adenocarcinoma masquerading as peritoneal metastases.

Authors:  Wei Xie; Linda K Green; Rishi A Patel; Syeling Lai
Journal:  Case Rep Pathol       Date:  2014-05-20

6.  Malignant Peritoneum Mesothelioma with Hepatic Involvement: A Single Institution Experience in 5 Patients and Review of the Literature.

Authors:  Shan-Shan Su; Guo-Qi Zheng; Ya-Gang Liu; Yue-Feng Chen; Zhao-Wei Song; Shu-Jing Yu; Ning-Ning Sun; Yu-Xin Yang
Journal:  Gastroenterol Res Pract       Date:  2016-03-16       Impact factor: 2.260

Review 7.  Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.

Authors:  Kimberly A Birnie; Cecilia M Prêle; Philip J Thompson; Bahareh Badrian; Steven E Mutsaers
Journal:  Oncotarget       Date:  2017-08-24

Review 8.  Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Authors:  Stergios Boussios; Michele Moschetta; Afroditi Karathanasi; Alexandros K Tsiouris; Foivos S Kanellos; Konstantina Tatsi; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2018-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.